This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Commercial genomics inquiry: written evidence

Published: 26 Apr 2019 in

In March 2019, the House of Commons Science and Technology Committee launched an inquiry into commercial genomic testing to establish what safeguards need to be put in place to protect those who get tested.

In our response, the Society outlined the safeguards we think need to be put in place to protect individuals who have genomic tests. These safeguards are related to: False positive and false negative results; False reassurance; Inaccurate interpretation and limited sensitivity; Indication-driven versus preventive screening; Benefit versus harm of genomic screening of healthy individuals; Privacy and confidentiality; and Wider impact on NHS services.

Read our response.